Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery.

Christiansen D, Earnest-Silveira L, Grubor-Bauk B, Wijesundara DK, Boo I, Ramsland PA, Vincan E, Drummer HE, Gowans EJ, Torresi J.

Sci Rep. 2019 Jun 25;9(1):9251. doi: 10.1038/s41598-019-45461-z.

2.

Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine.

Christiansen D, Earnest-Silveira L, Chua B, Meuleman P, Boo I, Grubor-Bauk B, Jackson DC, Keck ZY, Foung SKH, Drummer HE, Gowans EJ, Torresi J.

Sci Rep. 2018 Apr 24;8(1):6483. doi: 10.1038/s41598-018-24762-9.

3.

Antibody Responses to a Quadrivalent Hepatitis C Viral-Like Particle Vaccine Adjuvanted with Toll-Like Receptor 2 Agonists.

Christiansen D, Earnest-Silveira L, Chua B, Boo I, Drummer HE, Grubor-Bauk B, Gowans EJ, Jackson DC, Torresi J.

Viral Immunol. 2018 May;31(4):338-343. doi: 10.1089/vim.2017.0182. Epub 2018 Feb 28.

PMID:
29489437
4.

Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.

Gu J, Hardy J, Boo I, Vietheer P, McCaffrey K, Alhammad Y, Chopra A, Gaudieri S, Poumbourios P, Coulibaly F, Drummer HE.

J Virol. 2018 Apr 13;92(9). pii: e02066-17. doi: 10.1128/JVI.02066-17. Print 2018 May 1.

5.

An Optimized Hepatitis C Virus E2 Glycoprotein Core Adopts a Functional Homodimer That Efficiently Blocks Virus Entry.

McCaffrey K, Boo I, Owczarek CM, Hardy MP, Perugini MA, Fabri L, Scotney P, Poumbourios P, Drummer HE.

J Virol. 2017 Feb 14;91(5). pii: e01668-16. doi: 10.1128/JVI.01668-16. Print 2017 Mar 1.

6.

The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs.

Vietheer PT, Boo I, Gu J, McCaffrey K, Edwards S, Owczarek C, Hardy MP, Fabri L, Center RJ, Poumbourios P, Drummer HE.

Hepatology. 2017 Apr;65(4):1117-1131. doi: 10.1002/hep.28989. Epub 2017 Feb 14.

7.

Calsyntenin-1 mediates hepatitis C virus replication.

Awan Z, Tay ES, Eyre NS, Wu LE, Beard MR, Boo I, Drummer HE, George J, Douglas MW.

J Gen Virol. 2016 Aug;97(8):1877-87. doi: 10.1099/jgv.0.000511. Epub 2016 May 24.

PMID:
27221318
8.

Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line.

Earnest-Silveira L, Chua B, Chin R, Christiansen D, Johnson D, Herrmann S, Ralph SA, Vercauteren K, Mesalam A, Meuleman P, Das S, Boo I, Drummer H, Bock CT, Gowans EJ, Jackson DC, Torresi J.

J Gen Virol. 2016 Aug;97(8):1865-76. doi: 10.1099/jgv.0.000493. Epub 2016 May 4.

PMID:
27147296
9.

Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region.

Alhammad Y, Gu J, Boo I, Harrison D, McCaffrey K, Vietheer PT, Edwards S, Quinn C, Coulibaly F, Poumbourios P, Drummer HE.

J Virol. 2015 Dec;89(24):12245-61. doi: 10.1128/JVI.02070-15. Epub 2015 Sep 16.

10.

Role of conserved cysteine residues in hepatitis C virus glycoprotein e2 folding and function.

McCaffrey K, Boo I, Tewierek K, Edmunds ML, Poumbourios P, Drummer HE.

J Virol. 2012 Apr;86(7):3961-74. doi: 10.1128/JVI.05396-11. Epub 2012 Jan 25.

11.

Distinct roles in folding, CD81 receptor binding and viral entry for conserved histidine residues of hepatitis C virus glycoprotein E1 and E2.

Boo I, teWierik K, Douam F, Lavillette D, Poumbourios P, Drummer HE.

Biochem J. 2012 Apr 1;443(1):85-94. doi: 10.1042/BJ20110868.

PMID:
22240035
12.

Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 contain reduced cysteine residues essential for virus entry.

Fraser J, Boo I, Poumbourios P, Drummer HE.

J Biol Chem. 2011 Sep 16;286(37):31984-92. doi: 10.1074/jbc.M111.269605. Epub 2011 Jul 15.

13.

The variable regions of hepatitis C virus glycoprotein E2 have an essential structural role in glycoprotein assembly and virion infectivity.

McCaffrey K, Gouklani H, Boo I, Poumbourios P, Drummer HE.

J Gen Virol. 2011 Jan;92(Pt 1):112-21. doi: 10.1099/vir.0.026385-0. Epub 2010 Oct 6.

PMID:
20926639
14.
15.

Expression and characterization of a minimal hepatitis C virus glycoprotein E2 core domain that retains CD81 binding.

McCaffrey K, Boo I, Poumbourios P, Drummer HE.

J Virol. 2007 Sep;81(17):9584-90. Epub 2007 Jun 20.

16.

Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin.

Boo I, Fischer AE, Johnson D, Chin R, Giourouki M, Bharadwaj M, Bowden S, Torresi J, Drummer H.

J Clin Virol. 2007 Aug;39(4):288-94. Epub 2007 Jun 14.

PMID:
17569577
17.

A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virus.

Torresi J, Stock OM, Fischer AE, Grollo L, Drummer H, Boo I, Zeng W, Earnest-Silveira L, Jackson DC.

Hepatology. 2007 Apr;45(4):911-20.

PMID:
17393515
18.
19.
20.

[Abdominal pain, indigestion and eosinophilia].

Boo II, Risch L, Heijnen IA, Huber AR.

Rev Med Suisse. 2006 Mar 15;2(57):749-53. French.

PMID:
16604877

Supplemental Content

Support Center